Journal of Affective Disorders
Volume 118, Issue 1 , Pages 187-195 , November 2009

Zinc supplementation augments efficacy of imipramine in treatment resistant patients: A double blind, placebo-controlled study

  • Marcin Siwek

      Affiliations

    • Department of Psychiatry, Collegium Medicum, Jagiellonian University, Kraków, Poland
    • ,
  • Dominika Dudek

      Affiliations

    • Department of Psychiatry, Collegium Medicum, Jagiellonian University, Kraków, Poland
    • ,
  • Ian A. Paul

      Affiliations

    • Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, USA
    • ,
  • Magdalena Sowa-Kućma

      Affiliations

    • Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland
    • ,
  • Andrzej Zięba

      Affiliations

    • Department of Psychiatry, Collegium Medicum, Jagiellonian University, Kraków, Poland
    • ,
  • Piotr Popik

      Affiliations

    • Faculty of Public Health, Collegium Medicum, Jagiellonian University, Kraków, Poland
    • Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland
    • ,
  • Andrzej Pilc

      Affiliations

    • Faculty of Public Health, Collegium Medicum, Jagiellonian University, Kraków, Poland
    • Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland
    • ,
  • Gabriel Nowak

      Affiliations

    • Chair of Pharmacobiology, Collegium Medicum, Jagiellonian University, Kraków, Poland
    • Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland
    • Corresponding Author InformationCorresponding author. Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, PL 31-343 Kraków, Poland. Tel.: +48 12 6623 215; fax: +48 12 6374 500.

Received 22 June 2008 ,Revised 18 February 2009 ,Accepted 18 February 2009.

References 

  1. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry. 1961;4:561–571
  2. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry. 2000;47:351–354
  3. Bonne O, Vythilingam M, Inagaki M, Wood S, Neumeister A, Nugent AC, et al. Reduced posterior hippocampal volume in posttraumatic stress disorder. J. Clin. Psychiatry. 2008;69:1087–1091
  4. Carvalho AF, Cavalcante JL, Castelo MS, Lima MCO. Augmentation strategies for treatment-resistant depression: a literature review. J. Clin. Pharm. Ther. 2007;32:415–428
  5. Cieslik K, Klenk-Majewska B, Danilczuk Z, Wrobel A, Lupina T. Influence of zinc supplementation on imipramine effect in a chronic unpredictable stress (CUS) model in rats. Pharmacol. Rep. 2007;59:46–52
  6. Cucha MP, Machado DG, Bettino LEB, Capra JC, Rodrigues ALS. Interaction of zinc with antidepressants in the tail suspension test. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2008;32:1913–1920
  7. Dybała M, Siwek A, Poleszak E, Pilc A, Nowak G. Lack of NMDA-AMPA interaction in antidepressant-like effect of CGP 37849, an antagonist of NMDA receptor, in the forced swim test. J. Neural Transm. 2008;115:1519–1520
  8. Dziedzicka-Wasylewska M, Rogóż Z, Solich J, Dudek D, Wrobel A, Zieba A. Effect of joint administration of imipramine and amantadine on binding of [3H]7-OH-DPAT to dopamine D3 receptors in peripheral blood lymphocytes of the patients with drug-resistant unipolar depression. Pol. J. Pharmacol. 2002;54:703–706
  9. Franco JL, Posser T, Brocardo PS, Trevisan R, Uliano-Silva M, Gabilan NH, et al. Involvement of glutathione, ERK1/2 phophorylation and BDNF expression in the antidepressant-like effect of zinc. Behav. Brain Res. 2007;188:316–323
  10. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 1960;23:56–61
  11. Harvey BH, Jonker LP, Brand L, Heenop M, Stein DJ. NMDA receptor involvement in imipramine withdrawal-associated effects on swim stress, GABA levels and NMDA receptor binding in rat hippocampus. Life Sci. 2002;71:43–54
  12. Kirsh I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. Ploos. Med. 2008;5:260–268
  13. Kroczka B, Zieba A, Dudek D, Pilc A, Nowak G. Zinc exhibits an antidepressant-like effect in the forced swimming test in mice. Pol. J. Pharmacol. 2000;52:403–406
  14. Kroczka B, Branski P, Pałucha A, Pilc A, Nowak G. Antidepressant-like properties of zinc in rodent forced swim test. Brain Res. Bull. 2001;55:297–300
  15. Lamont SR, Paulls A, Stewart CA. Repeated electroconvulsive stimulation, but not antidepressant drugs, induces mossy fibre sprouting in the rat hippocampus. Brain Res. 2001;893:53–58
  16. Lee AL, Ogle WO, Sapolsky RM. Stress and depression: possible links to neuron death in the hippocampus. Bipolar Disord. 2002;4:117–128
  17. Maeng S, Zarate CA, Du J, Schlosser RJ, McCammon J, Chen G, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry. 2008;63:349–352
  18. Maes M, D'Haese PC, Scharpe S, D'Hondt PD, Cosyns P, De Broe ME. Hipozincemia in depression. J. Affect. Disord. 1994;31:135–140
  19. Maes M, Vandoolaeghe E, Neels H, Demedts P, Wauters A, Meltzer HY, et al. Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol. Psychiatry. 1997;42:49–358
  20. Maes M, De Vos N, Demedts P, Wauters A, Neels H. Lower serum zinc in major depression in relation tochanges in serum acute phase proteins. J. Affect. Disord. 1999;56:189–194
  21. MacQueen GM, Campbell S, McEwen BS, MacDonald K, Amano S, Joffe RT, et al. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc. Natl. Acad. Sci. 2003;100:1387–1392
  22. McElroy SL, Zarate CA, Cookson J, Suppes T, Huffman RF, Greene P, et al. A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression. J. Clin. Psychiatry. 2004;65:204–210
  23. McLoughlin IJ, Hodge JS. Zinc in depressive disorder. Acta Psychiatr. Scand. 1990;82:451–453
  24. Michaelson D, Amsterdam J, Apter J, Fava M, Londborg P, Tamura R, et al. Hormonal markers of stress response following interruption of selective serotonin reuptake inhibitor treatment. Psychoneuroendocrinology. 2000;25:169–177
  25. Nemeroff CB. Prevalence and management of treatment-resistant depression. J. Clin. Psychiatry. 2007;68:17–25
  26. Nierenberg AA, Ostacher MJ, Huffman JC, Ametrano RM, Fava M, Perlis RH. A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder. J. Occup. Environ. Med. 2008;50:428–436
  27. Nowak G, Schlegel-Zawadzka M. Alterations in serum and brain trace element levels after antidepressant treatment: part I. Zinc. Biol. Trace Elem. Res. 1999;67:85–92
  28. Nowak G, Redmond A, McNamara M, Paul IA. Swim stress increases the potency of glycine at the N-methyl-d-aspartate receptor complex. J. Neurochem. 1995;64:925–927
  29. Nowak G, Zięba A, Dudek D, Krośniak M, Szymaczek M, Schlegel-Zawadzka M. Serum trace elements in animal models and human depression. Part I. Zinc. Hum. Psychopharmacol. Clin. Exp. 1999;14:83–86
  30. Nowak G, Siwek M, Dudek D, Zieba A, Pilc A. Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Pol. J. Pharmacol. 2003;55:1143–1147
  31. Nowak G, Szewczyk B, Sadlik K, Piekoszewski W, Trela F, Florek E, et al. Reduced potency of zinc to interact with NMDA receptors in hippocampal tissue of suicide victims. Pol. J. Pharmacol. 2003;55:455–459
  32. Nowak G, Szewczyk B, Wieronska JM, Branski P, Palucha A, Pilc A, et al. Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res. Bull. 2003;61:159–164
  33. Nowak G, Szewczyk B, Pilc A. Zinc and depression. An update. Pharmacol. Rep. 2005;57:713–718
  34. Opoka W, Sowa-Kućma M, Kowalska M, Baś B, Gołembiowska K, Nowak G. Intraperitoneal zinc administration increases extracellular zinc in the rat prefrontal cortex. J. Physiol. Pharmacol. 2008;59:477–487
  35. Prescorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J. Clin. Psychopharmacol. 2008;28:631–637
  36. Rosa AO, Lin J, Calixto JB, Santos AR, Rodrigues AL. Involvement of NMDA receptors and l-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice. Behav. Brain Res. 2003;144:87–93
  37. Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch. Gen. Psychiatry. 2004;6:705–713
  38. Sanacora G, Kendel SF, Fenton L, Coric V, Krystal JH. Riluzole augmentation for treatment-resistant depression. Am. J. Psychiatry. 2004;161:2132
  39. Schlegel-Zawadzka M, Zieba A, Dudek D, Krosniak M, Szymaczek M, Nowak G. Effect of depression and of antidepressant therapy on serum zinc levels—a preliminary clinical study. In:  Roussel AM,  Anderson RA,  Favrier AE editor. Trace Elements in Man and Animals. vol. 10:New York: Kluwer Academic Plenum Press; 2000;p. 607–610
  40. Smart TG, Xie X, Krishek BJ. Modulation of inhibitory and excitatory amino acid receptor ion channels by zinc. Prog. Neurobiol. 1994;42:393–441
  41. Sowa-Kućma M, Legutko B, Szewczyk B, Novak K, Znojek P, Poleszak E, et al. Antidepressant-like activity of zinc: further behavioral and molecular evidence. J. Neural Transm. 2008;115:1621–1628
  42. Szewczyk B, Kata R, Nowak G. Rise in zinc affinity for the NMDA receptor evoked by chronic imipramine is species-specific. Pol. J. Pharmacol. 2001;53:641–645
  43. Szewczyk B, Branski P, Wieronska JM, Palucha A, Pilc A, Nowak G. Interaction of zinc with antidepressants in the forced swimming test in mice. Pol. J. Pharmacol. 2002;54:681–685
  44. Szewczyk G, Sowa M, Czupryn A, Wieronska JM, Branski P, Sadlik K, et al. Increase in synaptic hippocampal zinc concentration following chronic but not acute zinc treatment in rats. Brain Res. 2006;1090:69–75
  45. Szewczyk B, Poleszak E, Sowa M, Siwek M, Dudek D, Ryszewska-Pokraśniewicz B, et al. Antidepressant activity of zinc and magnesium in view of current hypotheses of antidepressant action. Pharmacol. Rep. 2008;60:588–599
  46. Szewczyk B, Poleszak E, Wlaz P, Wróbel A, Blicharska E, Cichy A, et al. The involvement of serotonergic system in the antidepressant effect of zinc in the forced swim test. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2009;33:323–329
  47. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J. Clin. Psychiatry. 1997;58(Suppl 13):23–29
  48. Vaidya VA, Siuciak JA, Du F, Duman RS. Hippocampal mossy fiber sprouting induced by chronic electroconvulsive seizures. Neuroscience. 1999;89:57–66
  49. Warden D, Rush AJ, Trivedi MH, Fva M, Wisniewski SR. The STAR⁎D Project results: a comprehensive review of findings. Curr. Psychiatry Rep. 2007;9:449–459
  50. Wyska E, Szymura-Oleksiak J, Opoka W, Baś B, Niewiara E, Pomierny L, et al. Pharmacokinetic interaction after joint administration of zinc and imipramine in forced swim test in mice. Pol. J. Pharmacol. 2004;56:479–484
  51. Zarate CA, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol. Psychiatry. 2005;57:430–432
  52. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an NMDA antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry. 2006;63:856–864

PII: S0165-0327(09)00081-0

doi: 10.1016/j.jad.2009.02.014

Journal of Affective Disorders
Volume 118, Issue 1 , Pages 187-195 , November 2009

Article Tools

* Image Usage & Resolution